EMA Authorised: Jalra (vildagliptin) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Jalra (vildagliptin) for the treatment of type 2 diabetes mellitus. Novartis Europharm Limited is the marketing authori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jalra (vildagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novartis Europharm Limited. Decision date: 05/12/2025